Biblio Discovery — Demo Discovery Service

6 hasil untuk "Mathieu Le Gars"

Menampilkan 1–6 · 0,89 detik · RSS

  1. Artikel Jurnal

    Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

    Dan H. Barouch; Kathryn E. Stephenson; JERALD C. SADOFF dkk.

    New England Journal of Medicine · 2021 · Inggris · OpenAlex Scopus

    To evaluate the 8-month durability of humoral and cellular immune responses after Ad26.COV2.S Vaccination

  2. Artikel Jurnal

    Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

    JERALD C. SADOFF; Glenda Gray; An Vandebosch dkk.

    New England Journal of Medicine · 2021 · Inggris · OpenAlex Scopus

    BACKGROUND: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. METHODS: viral particles) or placebo. The primary end…

  3. Artikel Jurnal Teks lengkap

    Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

    JERALD C. SADOFF; Mathieu Le Gars; Georgi Shukarev dkk.

    New England Journal of Medicine · 2021 · Inggris · OpenAlex Scopus

    BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26…

  4. Artikel Jurnal Teks lengkap

    Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

    JERALD C. SADOFF; Glenda Gray; An Vandebosch dkk.

    New England Journal of Medicine · 2022 · Inggris · OpenAlex Scopus

    BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate to…

  5. Artikel Jurnal Teks lengkap

    Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

    Galit Alter; Jingyou Yu; Jinyan Liu dkk.

    Nature · 2021 · Inggris · OpenAlex Scopus

    Abstract The Ad26.COV2.S vaccine 1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies 1 . However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains…

  6. Artikel Jurnal Teks lengkap

    Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

    Kathryn E. Stephenson; Mathieu Le Gars; JERALD C. SADOFF dkk.

    JAMA · 2021 · Inggris · OpenAlex

    Importance: Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective: To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2…